Antimicrobial peptides as therapeutic agents: opportunities and challenges

Mahlapuu, Margit; Björn, Camilla; Ekblom, Jonas

doi:10.1080/07388551.2020.1796576

Cited by 247 publications

(211 citation statements)

References 120 publications

Supporting

Mentioning

206

Contrasting

Unclassified

Order By: Relevance

“…The most worrying concern of an antiviral peptide is its immunogenic pro le [52]. A low immunogenic pro le is the desired characteristic of an antiviral peptide because a low immunogenic pro le reduces the chances of elimination by the host defense system [53]. Therefore, we also investigate the immunogenic pro le of the AVPs.…”

Section: Resultsmentioning

confidence: 99%

A novel peptide analogue of spike glycoprotein shows antiviral properties against SARS-CoV-2: An in silico approach through molecular docking, molecular dynamics simulation and MM-PB/GBSA calculations

Dutta

Elmezayen

Al-Obaidi

et al. 2020

Preprint

View full text Add to dashboard Cite

At the very beginning of the new decade, the COVID-19 pandemic has badly hit modern human societies. SARS-CoV-2, the causative agent of COVID-19 carries dozens of new mutations in its genome. Herein, we made an effort to find new antiviral peptides (AVPs) against SARS-CoV-2. Gladly, with the help of Machine Learning algorithms, and Supported Vector Machine, we have invented three new AVPs against the SARS-CoV-2. Antiviral peptides viz., Seq12, Seq12m, and Seq13m can block the receptor binding domain (RBD) of the SARS-CoV-2, necessary for communication with the angiotensin-converting enzyme 2 (ACE2). In addition, these AVPs retain their antiviral properties, even after the insertion of dozens of new mutations (Rosetta, and FoldX based) in the RBD. Further, Seq12, and Seq12m showed negligible cytotoxicity. Besides, the binding free energy calculated using MM-PB/GBSA method is also in agreement with the molecular docking studies performed using HADDOCK. Furthermore, the molecular interactions between AVPs and the viral membrane protein (M) also showed a thermodynamically favorable interaction, suggesting it could eventually inhibit the viral re-packaging process. In conclusion, this study suggests AVPs viz., Seq12, Seq12m, and Seq13m embrace importance as a potential anti-SARS-CoV-2 therapeutic. These AVPs could also aid virus diagnostic tools in the future.

show abstract

Section: Resultsmentioning

confidence: 99%

A novel peptide analogue of spike glycoprotein shows antiviral properties against SARS-CoV-2: An in silico approach through molecular docking, molecular dynamics simulation and MM-PB/GBSA calculations

Dutta

Elmezayen

Al-Obaidi

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Cathelicidins (LL-37), human β-defensins 3 (HBD-3), magainins, and temporins are the most prevalent AMPs. They own anti-infective and immunomodulatory activity toward a broad spectrum of Gram-positive and Gram-negative bacteria, including MRSA , and quinolone-resistant Enterobacteriaceae , fungi, and viruses [ 105 ]. Their antimicrobial activity lies in the positive charges of arginine and lysine residues [ 106 ] and hydrophobicity [ 106 ], through which AMPs attach to the bacteria membrane.…”

Section: Promising Antimicrobial Compounds For the Treatment Of Cardiac And Orthopaedic Device-associated Infectionsmentioning

confidence: 99%

Trends in Managing Cardiac and Orthopaedic Device-Associated Infections by Using Therapeutic Biomaterials

et al. 2021

View full text Add to dashboard Cite

Over the years, there has been an increasing number of cardiac and orthopaedic implanted medical devices, which has caused an increased incidence of device-associated infections. The surfaces of these indwelling devices are preferred sites for the development of biofilms that are potentially lethal for patients. Device-related infections form a large proportion of hospital-acquired infections and have a bearing on both morbidity and mortality. Treatment of these infections is limited to the use of systemic antibiotics with invasive revision surgeries, which had implications on healthcare burdens. The purpose of this review is to describe the main causes that lead to the onset of infection, highlighting both the biological and clinical pathophysiology. Both passive and active surface treatments have been used in the field of biomaterials to reduce the impact of these infections. This includes the use of antimicrobial peptides and ionic liquids in the preventive treatment of antibiotic-resistant biofilms. Thus far, multiple in vivo studies have shown efficacious effects against the antibiotic-resistant biofilm. However, this has yet to materialize in clinical medicine.

show abstract

“…A growing number of AMPs have been proposed as effective agents that could be potentially used as not only bactericidal products, anti-persister agents, food additives, and foodborne pathogen detectors, but also immunity regulators and wound healers. Actually, a range of AMPs are proven as anti-infective agents and are currently assessed in the last clinical trial stage trail [163]. However, due to the complexity of application of AMPs, only around 60 AMPs are approved as therapeutic peptides [164] and 7 AMPs are permitted by the U.S. Food and Drug Administration for now [165].…”

Section: Challenges With Amps Applicationmentioning

confidence: 99%

Bacterial Persister-Cells and Spores in the Food Chain: Their Potential Inactivation by Antimicrobial Peptides (AMPs)

Liu

Brul

Zaat

2020

IJMS

View full text Add to dashboard Cite

The occurrence of bacterial pathogens in the food chain has caused a severe impact on public health and welfare in both developing and developed countries. Moreover, the existence of antimicrobial-tolerant persisting morphotypes of these pathogens including both persister-cells as well as bacterial spores contributes to difficulty in elimination and in recurrent infection. Therefore, comprehensive understanding of the behavior of these persisting bacterial forms in their environmental niche and upon infection of humans is necessary. Since traditional antimicrobials fail to kill persisters and spores due to their (extremely) low metabolic activities, antimicrobial peptides (AMPs) have been intensively investigated as one of the most promising strategies against these persisting bacterial forms, showing high efficacy of inactivation. In addition, AMP-based foodborne pathogen detection and prevention of infection has made significant progress. This review focuses on recent research on common bacterial pathogens in the food chain, their persisting morphotypes, and on AMP-based solutions. Challenges in research and application of AMPs are described.

show abstract

Antimicrobial peptides as therapeutic agents: opportunities and challenges

Cited by 247 publications

References 120 publications

A novel peptide analogue of spike glycoprotein shows antiviral properties against SARS-CoV-2: An in silico approach through molecular docking, molecular dynamics simulation and MM-PB/GBSA calculations

A novel peptide analogue of spike glycoprotein shows antiviral properties against SARS-CoV-2: An in silico approach through molecular docking, molecular dynamics simulation and MM-PB/GBSA calculations

Trends in Managing Cardiac and Orthopaedic Device-Associated Infections by Using Therapeutic Biomaterials

Bacterial Persister-Cells and Spores in the Food Chain: Their Potential Inactivation by Antimicrobial Peptides (AMPs)

Contact Info

Product

Resources

About